Progress in defining and treating high-risk neuroblastoma: Lessons from the bench and bedside

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1003-1004

  Volchenboum, Samuel L ^a   Cohn, Susan L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANAPLASTIC LYMPHOMA KINASE; BUSULFAN; ENZYME INHIBITOR; ISOTRETINOIN; MELPHALAN;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE DURATION; DRUG INFUSION; DRUG MEGADOSE; EDITORIAL; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEUROBLASTOMA; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 61449242771     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.2739     Document Type: Editorial

References (16)

1. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007
2. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 27:1007-1013, 2009
3. Canete A, Gerrard M, Rubie H, et al: Poor survival for infants with MYCW-amplified metastatic neuroblastoma despite intensified treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 27:1014-1019, 2009
4. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al: Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
5. Matthay KK, Quach A, Huberty J, et al: Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A New Approaches to Neuroblastoma Therapy phase I study. J Clin Oncol 27:1020-1025, 2009
6. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098-2103, 1971
7. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
8. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
9. Cohn SL, Pearson ADJ, London WB, et al: The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J Clin Oncol 27:289-297, 2009
10. Berthold F, Boos J, Burdach S, et al: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 6:649-658, 2005
11. Pritchard J, Cotterill SJ, Germond SM, et al: High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44:348-357, 2005
12. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005
13. Mossé YP, Laudenslager M, Longo L, et al: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935, 2008
14. Chen Y, Takita J, Choi YL, et al: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974, 2008
15. Janoueix-Lerosey I, Lequin D, Brugieres L, et al: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970, 2008
16. George RE, Sanda T, Hanna M, et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978, 2008